Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents
Despite hundreds of children successfully treated in phase 2 and pilot trials around the world, the failure of phase 3 with Servier illustrates the difficulty of developing a universal treatment for autism. See the Press Release :
